Drugmakers of Ozempic Face Claims of Failed Side Effects Warning in Multidistrict Litigation Case

Judge Karen Martson has been appointed to oversee a massive, multi-district lawsuit, against Novo Nordisk and Eli Lilly, Both drugmakers of GLP-1 class medications. Their popular diabetes and obesity medications include Ozempic, Wegovy, Mounjaro, Trulicity and Zepbound.

A Kaiser Family Foundation poll states that about one in eight U.S. adults have taken a drug belonging to the GLP-1 class of medications. The lawsuit alleges that the drugmakers neglected to adequately warn about “prolonged, life-threatening digestive dysfunction” potentially caused by their medications. Side effects include gastroparesis, severe vomiting, and gallbladder issues.

This blog is intended to provide information to the general public and to practitioners about developments that may impact Oregon class actions.

Sign up to receive Class Actions Blog posts in your inbox!

Steve Larson

An experienced trial lawyer who handles both hourly and contingent fee cases, Steve has expertise in class actions, environmental clean-up litigation, antitrust litigation, securities litigation, corporate disputes, intellectual property disputes, unfair competition claims, and disputes involving family wealth. Steve regularly represents individuals and businesses in federal and state court and has obtained class-wide recovery in multiple class actions. A veteran practitioner, Steve’s clients value his creative approach to resolving complex litigation matters.


Legal Disclaimer

The information contained in this blog does not constitute legal advice, and does not create an attorney-client relationship. We make no claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained in or linked to this blog.